Bruker Unveils Groundbreaking $100 Plasma Proteomics Platform, Pioneering Advances in Glycoproteomics and Metaproteomics
Bruker Corporation has announced a revolutionary leap in 4D-Proteomics™, offering deep, high-fidelity plasma proteomics for just $100 per sample, marking a significant step forward in large-scale, unbiased proteomic studies. Leveraging the powerful timsTOF technology and PreOmics ENRICH™ methods, Bruker enables high-specificity protein identification (99% specificity, 1% FDR) with typical sequence coverage exceeding 10 peptides per protein. This cost-efficient platform is set to transform plasma proteomics by allowing deep proteome exploration at scale, addressing a wide range of biomedical applications.
Key advancements include the introduction of diagonal-PASEF® methods for immunopeptidomics and PTM analysis. Developed in collaboration with leading researchers, this innovation improves the precision of protein quantification and ensures better sampling with higher confidence, making it ideal for studying complex proteomic interactions. Bruker’s proprietary midia-PASEF and synchro-PASEF further enhance the platform’s capabilities, offering three-fold signal strength improvements and enabling large-scale, high-throughput acquisition without sacrificing accuracy.
Bruker also introduces a breakthrough in glycoproteomics with Glyco-PASEF® on its ultra-sensitive timsTOF Ultra 2 system. This high-sensitivity glycopeptide analysis technology, powered by ENRICHplus and GlycoScape software, doubles the number of glycopeptides identified, providing unprecedented depth for glycobiology research. Researchers can now explore human plasma samples with greater accuracy, advancing the understanding of disease mechanisms through detailed glycoproteomic profiling.
In addition, Bruker has pushed the boundaries of machine learning in proteomics with TIMSrescore™—a cutting-edge tool that increases peptide and protein identifications for immunopeptidomics and metaproteomics, achieving ultra-high stringency (99.9% specificity at 0.1% FDR). This is critical for distinguishing highly similar proteins and PTMs, especially in microbial proteomics, where precise identification is crucial for scientific discovery.
The impact of these advancements is amplified by Bruker’s introduction of 4D-Multiomics, combining proteomics, lipidomics, and metabolomics into a single platform for more comprehensive biological insights. With new visualization tools in ProteoScape™ and MetaboScape®, users can analyze large datasets in real-time, utilizing dimensional reduction techniques and interactive multiomics visualizations to accelerate data interpretation and facilitate biological breakthroughs.
Researchers and institutions, including Dana-Farber Cancer Institute and the University of Oxford, are already leveraging Bruker’s next-generation timsTOF technology to unlock new insights into proteomic dynamics, genomic alterations, and small-molecule interactions. As Bruker continues to innovate and integrate proteomic technologies, the company’s platform is set to lead the next wave of discoveries in precision medicine, disease research, and therapeutic development.
By delivering deep plasma proteomics with unmatched precision at a groundbreaking price point, Bruker is democratizing access to high-sensitivity proteomics, advancing the field of life sciences, and pushing the boundaries of what’s possible in biomedical research.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.
